CK - 医索

找到约 399 条结果

Use of artificial intelligence-based digital pathology to predictoutcomes for immune checkpoint inhibitor therapy in advancedgastro-esophageal cancer.

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs lenvatinib or sorafenib asfirst-line treatment for unresectable hepatocellularcarcinoma first results from CheckMate 9DW

医客学院 - 会议报告集

New Tricks With Old Tools Acrossthe Spectrum of Pancreatic cancer

医客学院 - 会议报告集

International, open-label phase 2 study of regorafenibplus pembrolizumab in patients with advancedhepatocellular carcinoma previously treated withimmune checkpoint inhibitors

医客学院 - 会议报告集

ECOG-ACRIN EAZ171 Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TlPN) in Black women with early-stage breast cancer

医客学院 - 会议报告集

Neoadjuvant nivolumab plus chemotherapy vschemotherapy in patients with resectable NSCLC4-year update from CheckMate 816

医客学院 - 会议报告集

Clinical outcomes with perioperative nivolumab bynodal status among patients with stage lll resectableNSCLCresults from the phase 3 CheckMate 77T study

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs chemotherapy as first-linetreatment for microsatellite instability-highmismatchrepairdeficient metastatic colorectal cancer expandedefficacy analysis from CheckMate 8HW

医客学院 - 会议报告集

Durable complete responses to PD-1 blockadealone in dMMR locally advanced rectal cancer

医客学院 - 会议报告集

《NEJM》临床三期发表：手术前后都给与免疫治疗，显著延长患者生存期

纳武利尤单抗是一种全人源抗程序性死亡蛋白1（PD-1）抗体，与铂类双药化疗联用已成为可切除非小细胞肺癌（NSCLC）患者的标准新辅助治疗。多项2期试验及里程碑式的3期CheckMate 816试验均显示，纳武利尤单抗联合化疗作为新辅助治疗能显著.....

学术资讯 - 超热文章

首页
上一页
1
2
3
4
5
...
39
40
下一页
尾页

今日实时热搜